Imitex Presents at AusBiotech International Conference
Melbourne, Australia — 22 October 2025
Imitex today presented at the Early Stage Innovation Forum (ESIF) during the AusBiotech International Conference in Melbourne, one of the Asia-Pacific region's leading gatherings of biotechnology investors and industry leaders.
Professor Sean McGee, Co-founder and Chief Scientific Officer, presented an overview of Imitex's AI-enabled drug discovery platform and the commercial opportunity in exercise mimetics — including the company's unique MEF2 activation approach and its potential as a combination therapy alongside GLP-1 weight-loss drugs such as Ozempic and Wegovy.
The presentation generated strong interest from potential investors and partners attending the forum.
"Being selected to present at ESIF reflects the quality of the science and the timeliness of what we're building," said Professor McGee. "The response reinforced our view that the market is ready for a first-in-class MEF2 activator, and that the GLP-1 muscle loss problem is now firmly on the radar of the investment community."